Core Viewpoint - Investors in Ultragenyx Pharmaceutical Inc. have the opportunity to lead a securities fraud lawsuit due to misleading statements regarding the company's drug setrusumab and its clinical trials [1][5][6]. Group 1: Lawsuit Details - The lawsuit involves claims that Ultragenyx provided investors with overly positive information about the expected results of its Phase III studies for setrusumab, which is intended for treating Osteogenesis Imperfecta [5]. - Defendants allegedly made materially false statements about setrusumab's effectiveness, suggesting it would reduce fracture rates, while concealing the true risks and limitations of the study protocols [6]. - The lawsuit asserts that these misleading statements led to Ultragenyx securities being purchased at artificially inflated prices, resulting in investor losses when the true information became public [6]. Group 2: Class Action Participation - Investors who purchased Ultragenyx common stock between August 3, 2023, and December 26, 2025, can join the class action lawsuit without incurring out-of-pocket fees through a contingency fee arrangement [2]. - To serve as lead plaintiff, interested parties must file a motion with the court by April 6, 2026 [3]. - The Rosen Law Firm encourages investors to select qualified legal counsel with a successful track record in securities class actions [4].

Core Viewpoint - PomDoctor Ltd. is facing a securities fraud lawsuit, with a lead plaintiff deadline set for April 7, 2026, for investors who purchased securities during the specified class period from October 9, 2025, to December 11, 2025 [1]. Group 1: Lawsuit Details - The lawsuit alleges that PomDoctor made false and misleading statements and failed to disclose critical information regarding a fraudulent stock promotion scheme involving social media misinformation and impersonation of financial professionals [5]. - It is claimed that insiders used offshore accounts to facilitate the coordinated dumping of shares during a price inflation campaign, which was not disclosed in PomDoctor's public statements [5]. - The lawsuit asserts that PomDoctor's risk disclosures omitted any mention of the false rumors and artificial trading activity that influenced the stock price, leading to materially misleading positive statements about the company's business and prospects [5]. Group 2: Class Action Participation - Investors who purchased PomDoctor securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, investors can submit a form online or contact the Rosen Law Firm for more information [3][6]. - A class has not yet been certified, meaning investors are not represented by counsel unless they retain one, and they can choose to remain absent from the class [7].

Core Viewpoint - Rosen Law Firm is reminding investors of BlackRock TCP Capital Corp. about the opportunity to lead a securities fraud lawsuit, with a deadline for lead plaintiff applications set for April 6, 2026 [1]. Group 1: Lawsuit Details - The class period for the lawsuit is defined as between November 6, 2024, and January 23, 2026 [1]. - Investors who purchased BlackRock TCP securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - The lawsuit alleges that defendants made materially false and misleading statements and failed to disclose adverse facts about BlackRock TCP's business and operations [5]. Group 2: Allegations Against BlackRock TCP - Specific allegations include that BlackRock TCP's investments were not being valued appropriately, and that efforts at portfolio restructuring were ineffective [5]. - The lawsuit claims that BlackRock TCP's unrealized losses were understated and its net asset value (NAV) was overstated, leading to misleading positive statements about the company's prospects [5]. Group 3: Next Steps for Investors - Investors interested in joining the class action can do so by visiting the provided link or contacting the law firm directly [3][6]. - A class action lawsuit has already been filed, and potential lead plaintiffs must act by the April 6, 2026 deadline [3].

Core Viewpoint - Shareholders of Super Micro Computer have filed a lawsuit alleging securities fraud due to the company's failure to disclose its reliance on sales to China, which allegedly violated U.S. export laws, leading to criminal charges against a co-founder and others [1][2]. Group 1: Lawsuit Details - The proposed class action lawsuit was filed in San Francisco federal court, claiming that Super Micro overstated its business prospects and inflated its stock price by not disclosing that a significant portion of server sales were directed to Chinese companies [2]. - The lawsuit seeks unspecified damages for Super Micro investors for the period between April 30, 2024, and March 19, 2026 [5]. Group 2: Impact on Company - Following the announcement of criminal charges against co-founder Yih-Shyan Liaw and others, Super Micro's shares plummeted by 33% on March 20, resulting in a loss of approximately $6.1 billion in market value [3]. - The lawsuit also names Chief Executive Charles Liang and Chief Financial Officer David Weigand as defendants [4]. Group 3: Criminal Case Context - Prosecutors allege that Liaw and Chang directed a Southeast Asian company to purchase servers containing Nvidia chips, with the company reportedly buying $2.5 billion worth of servers in 2024 and 2025 [4]. - Super Micro has stated that it is cooperating with the government and that the alleged criminal conduct is against its policies [5].

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating Atara Biotherapeutics, Inc. for potential violations of federal securities laws on behalf of investors who may have incurred losses [1] Investigation Details - The investigation pertains to disclosures made by Atara on January 16, 2025, regarding its operations and financial status [1]

Core Viewpoint - Nektar Therapeutics is facing a securities fraud class action lawsuit due to alleged misrepresentations regarding the REZOLVE-AA trial, which may have impacted investor decisions and the company's credibility [3]. Group 1: Lawsuit Details - The lawsuit claims that from February 26, 2025, to December 15, 2025, Nektar failed to disclose that enrollment in the REZOLVE-AA trial did not adhere to required protocols [3]. - It is alleged that this failure is likely to have a significant negative impact on the trial's results, leading to overstated claims about the trial's integrity and prospects [3]. - Consequently, the positive statements made by Nektar regarding its business and operations were materially misleading and lacked a reasonable basis [3]. Group 2: Investor Participation - Investors who suffered losses related to Nektar Therapeutics have the opportunity to lead the class action lawsuit, with a deadline for participation set for May 5, 2026 [2]. - Interested investors can contact the Law Offices of Frank R. Cruz for more information or to participate in the lawsuit [4].

Core Viewpoint - BlackRock TCP Capital Corp. is facing a class action lawsuit due to allegations of misleading investors regarding its business prospects and financial disclosures [2][4]. Group 1: Allegations and Financial Disclosures - The class action was filed on behalf of investors who acquired BlackRock TCP securities between November 6, 2024, and January 23, 2026 [1]. - Allegations include failure to disclose that the company's investments were not being timely or appropriately valued, and that efforts at portfolio restructuring were ineffective [2]. - The company's unrealized losses were understated, leading to an overstatement of its net asset value (NAV) [2]. - On January 23, 2026, BlackRock TCP disclosed that its NAV per share was between $7.05 and $7.09, which was 19% lower than the previous quarter and 23.4% lower than the previous year [3]. Group 2: Stock Performance and Investor Actions - Following the financial disclosure, BlackRock TCP's stock price fell by $0.76, or 12.97%, closing at $5.10 per share on January 26, 2026 [3]. - Shareholders interested in participating in the class action must file their papers by April 6, 2026, to serve as lead plaintiff [4].

Core Viewpoint - Mereo BioPharma Group plc is facing a class action lawsuit due to allegations of misleading investors regarding the Phase 3 ORBIT and COSMIC studies for its drug setrusumab, which did not meet its primary endpoints [2][3]. Group 1: Allegations and Lawsuit Details - The class action was filed on behalf of investors who purchased Mereo's American Depository Shares (ADS) between June 5, 2023, and December 26, 2025 [1]. - The lawsuit claims that Mereo provided investors with optimistic statements about the expected results of the Phase 3 studies while concealing material adverse facts about the studies' true outcomes [2]. - Specifically, the studies failed to achieve their primary endpoint of reducing annualized clinical fracture rates compared to placebo or bisphosphonate control groups [2][3]. Group 2: Impact on Share Price - Following the announcement on December 29, 2025, that neither the ORBIT nor COSMIC studies met their primary endpoints, Mereo's ADS price plummeted from $2.31 to $0.29, representing a decline of over 87.7% [3]. Group 3: Shareholder Actions - Shareholders interested in participating in the class action must submit their papers to the court by April 6, 2026, to serve as lead plaintiff [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4].

Core Viewpoint - Grocery Outlet Holding Corp. is facing a securities fraud class action lawsuit due to alleged misleading statements regarding its rapid store expansion and financial performance [3]. Group 1: Lawsuit Details - The lawsuit claims that from August 5, 2025, to March 4, 2026, the company failed to disclose that it had "expanded too quickly" into new stores [3]. - It is alleged that the company's strong financial and operational growth was artificially supported by excessive rapid store expansion [3]. - The company was reportedly unable to achieve sustainable growth necessary to meet its previously set guidance [3]. - The restructuring plan of the company would require further optimization, including significant store closures and asset write-downs [3]. - Positive statements made by the defendants regarding the company's business, operations, and prospects were claimed to be materially misleading and lacked a reasonable basis [3].

Core Viewpoint - Investors in Gartner, Inc. have the opportunity to lead a securities fraud class action lawsuit due to alleged misleading statements regarding the company's ability to meet revenue targets and maintain growth rates [1][3]. Group 1: Lawsuit Details - The lawsuit alleges that between February 4, 2025, and February 2, 2026, Gartner failed to disclose its inability to handle industry challenges, which affected its consulting revenue targets and CV growth rate [3]. - Defendants are accused of making materially misleading statements about the company's business operations and prospects, lacking a reasonable basis for their claims [3]. Group 2: Participation Information - Investors who suffered losses related to Gartner are encouraged to participate in the ongoing lawsuit, with a lead plaintiff deadline set for May 18, 2026 [2][4]. - Interested parties can contact the Law Offices of Frank R. Cruz for more information or to learn about their rights regarding the lawsuit [4][5].